INTRODUCTION
Hematopoiesis in the human conceptus progresses in a wavelike manner in several different embryonic sites: the yolk sac (YS), the splanchnopleura/aorta-gonad-mesonephros (AGM) region, the liver, and the bone marrow (BM) (Tavian and Peault, 2005; Zambidis et al., 2006) . Blood generation begins at day 16 of development in the YS with the production of primitive erythroid cells. At day 19, the intraembryonic splanchnopleura becomes hematopoietic. The emergence of multipotent progenitors and HSCs, organized in clusters of cells closely adherent to the ventral wall of the dorsal aorta, starts at day 27 in the developing splanchnopleura/AGM region (Tavian et al., 1996 (Tavian et al., , 1999 (Tavian et al., , 2001 ). Starting at day 30, the first erythroid progenitors (BFU-E, burst forming unit erythroid) are found in the liver, with multilineage hematopoietic progenitors (CFU-Mix or -GEMM; colony forming unit granulocyte, erythroid, macrophage, megakaryocyte) appearing in this tissue at week 13 (Hann et al., 1983) . Hematopoietic progenitors and long-term culture-initiating cells have been found in the human placenta at 8-17 weeks in gestation (Barcena et al., 2009; Zhang et al., 2004) . Thereafter, the BM becomes hematopoietic. This sequence of hematopoietic events closely parallels that found in the mouse conceptus, in which the spatial/temporal appearance and the quantitative/ qualitative characteristics of hematopoietic progenitor and stem cells have been carefully mapped (Ferkowicz et al., 2003; Kumaravelu et al., 2002; Medvinsky and Dzierzak, 1996; Palis et al., 1999) . Importantly, the developing hematopoietic cells in the conceptus are increasing in their complexity (multilineage and higher proliferative potentials) and culminate with the generation of adult-type HSCs that sustain hematopoiesis throughout adult life (Dzierzak and Speck, 2008) . While the YS generates the transient embryonic erythroid cells, the AGM is the first tissue to generate more complex hematopoietic progenitors and stem cells (Cumano et al., 1996; Medvinsky and Dzierzak, 1996) . The liver and the BM are thought to be colonized by these cells and provide a potent supportive microenvironment for the growth of the fetal and life-long blood system.
In addition to the AGM (Cumano et al., 1996; de Bruijn et al., 2000; Medvinsky and Dzierzak, 1996) , the chorioallantoic placenta of the mouse conceptus generates and supports hematopoietic cells at early developmental stages (Alvarez-Silva et al., 2003; Corbel et al., 2007; Gekas et al., 2005; Ottersbach and Dzierzak, 2005; Rhodes et al., 2008; Zeigler et al., 2006) . Quantitatively, the midgestation mouse placenta contains more hematopoietic progenitors and HSCs than the AGM region and the YS, indicating that the placenta provides a potent supportive microenvironment for HSC amplification and may be, with the liver, a predominant source of adult BM HSCs (Alvarez-Silva et al., 2003; Gekas et al., 2005; Kumaravelu et al., 2002; Ottersbach and Dzierzak, 2005) . In contrast to the mouse, there is little information concerning the hematopoietic potential of the human placenta (Bailo et al., 2004; Barcena et al., 2009; Challier et al., 2005; Zhang et al., 2004) . Human studies have focused on umbilical cord blood (UCB), revealing that it is an important and easily accessible source of potent hematopoietic progenitors and HSCs for clinical transplantation procedures (Tse et al., 2008) . However, the HSC dose limitation in UCB samples and the increasing transplantation needs for treating hematologic disorders has stimulated the search for additional sources of potent HSCs and/or improved methods of ex vivo amplification of HSCs prior to transplantation.
Generally, the human placenta has been thought to function as a facilitator of nutrient and waste exchange between the mother and fetus, a provider of immunoprotection for the fetus, and a producer of important factors and hormones for fetal growth (Gude et al., 2004) . In this report, we present data showing that the human placenta beginning from gestation week 6 onward contains fetal-derived immature hematopoietic progenitors and stem cells, differentially expressing CD34 through ontogeny. Furthermore, mesenchymal stromal cells, isolated from human placenta throughout development that we identify as pericytelike cells, can support the in vitro maintenance of human cord blood hematopoietic progenitors. Together, our results show that the human placenta is a potent hematopoietic niche and a potentially useful source of cells at term for regenerative medicine.
RESULTS

Human Placenta Contains Hematopoietic Progenitor Cells throughout Gestation
The human term placenta is comprised of the highly vascular fetal-derived chorionic plate and villi and maternally-derived blood components that circulate in the intervillous space. We examined whether the human placenta obtained at the time of delivery contains hematopoietic progenitors. Blood from inside the placenta was collected (placenta blood). The remaining cells inside the vasculature were collected in wash steps (vessels PBS) and following collagenase treatment (vessels collagenase). Finally, the placenta was dissociated after enzymatic treatment (placenta collagenase) ( Figure 1A ).
Flow cytometric analysis for CD34 and CD38 markers was performed on human placenta cell populations and UCB (Figure 1B , was found in the vessel collagenase and placenta collagenase cell preparations. Some of these cells coexpress CD31, but not CD45, and represent a population of endothelial cells ( Figure S1 available online).
Hematopoietic progenitor activity in term placental cell preparations was tested in the colony forming unit (CFU) assay. Colonies with typical morphology representing all hematopoietic lineages were found in both the vessel and placenta preparations-BFU-E, CFU-G, CFU-M, CFU-GM, and CFU-Mix ( Figure S2 ). The combined number of CFU-Cs in the placenta vessels and tissue obtained at the time of delivery (38 weeks) was found to be 8000 per 10 5 CD34 + cells ( Figure 1C ) and is a lower frequency than that found in UCB (23,000 per 10 5 CD34 + cells) or placental blood. This is a slight underestimate of placenta progenitor frequency since the CD34 ++ CD38 À population contains a proportion of endothelial cells: 19% for placenta vessels and 37% for tissue ( Figure S1 ). Clonogenic hematopoietic assays were also performed on placentas obtained from the first and second gestational trimesters. Colonies of all erythromyeloid lineages were found beginning at gestational week 6, the earliest stage placenta tested ( Figure 1D ), and were in both the CD34 + and CD34 À cell fractions. While the frequency of BFU-E remained similar between placentas obtained at gestational weeks 6, 9, and 15, abundant increases (up to 10-fold) of CFU-GM and CFU-Mix were found beginning at week 9. Until week 9, CFU-GM and CFU-Mix are mainly in the CD34 À placenta fraction. (Coulombel, 2004) . Published results from developmental studies show that the mouse placenta contains a high number of HSCs during midgestation (Gekas et al., 2005; Ottersbach and Dzierzak, 2005) . Since the analogous developmental period in the human begins at approximately week 6 in gestation, first and second trimester human placentas (total of 17) were examined for hu-SRCs. Placenta cells were injected into 47 NOD-SCID recipients (Table 1) , and multilineage engraftment was measured by flow cytometry and PCR. Figure 2A shows PCR results of hematopoietic tissue DNA from recipients receiving male 6, 9, and 19 week placenta cells. The male Y-chromosome-specific AMELY fragment was found in the blood, spleen, and BM, demonstrating that engraftment was due to placenta cells from the fetal part of the placenta. Flow cytometric analysis of the recipient injected with week 9 placenta (TCB) cells shows multilineage hematopoietic engraftment ( Figure 2B ). Human (h)CD45 + cells were found in the blood, BM, and spleen and were of the myeloid (CD15 + ) and B lymphoid (CD19 + ) lineages. A small population of hCD34 + CD38 À cells, indicative of immature hematopoietic progenitors, was found in the recipient BM. BM cells from this repopulated mouse produced colonies of all myeloerythroid lineages ( Figure 2C ),
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Human Placenta Is a Potent Hematopoietic Niche including the most immature multilineage colonies, CFU-Mix. PCR analysis of DNA prepared from individual CFU and pooled CFU verified that these human progenitors were fetal-derived ( Figure 2D ). Thus, early gestational stage human placenta cells home to the BM and provide multilineage hematopoietic repopulation of NOD-SCID mice.
Engraftment of NOD-SCID mice with placenta cells from female conceptuses was tested by PCR for human chromosome 17 (hChr 17) alpha-satellite DNA (Figure 2A, TC69A ), followed by a forensic PCR to discriminate fetal-from maternal-derived engraftment. Fifteen highly polymorphic short tandem repeat (STR) loci normally used for human identity testing were measured, and the STR profiles of recipient NOD-SCID hematopoietic tissue DNAs were compared to embryo STR profiles. As shown for the TC69A placenta ( Figure 2E ), the STR profiles of the spleen and BM cells of the NOD-SCID recipient were identical to the profile of the embryo, thus demonstrating exclusive engraftment from fetal-derived female placenta cells. In summary, of the 17 placentas transplanted into a total of 47 recipients, 14 recipients (30%) were repopulated by hu-SRCs of fetal placenta origin (Table 1) .
To further characterize the placentaderived hu-SRCs, transplantation experiments into NOD-SCID and Rag gC À/À mice were performed with placenta cells sorted on the basis of expression of the CD34 marker. As shown in Table 2 , HSCs are both in CD34 + and CD34 À fractions in 6-week-old placenta, the earliest time point tested. By 16 to 18 weeks, the HSC population appears to be enriched in the CD34 + fraction. An example of human multilineage analyses in a Rag gC À/À recipient is shown ( Figure S3 ).
Human Full-Term Placenta Contains NOD-SCID Hematopoietic Repopulating Cells
Previously, it was shown that HSCs were almost undetectable in the mouse placenta at term (E18) (Gekas et al., 2005) . To examine if this was also the case for the human placenta, cells from term human placenta vessels and tissues were prepared and injected into NOD-SCID mice. Recipients were analyzed at 5 months posttransplantation for human hematopoietic cell engraftment by flow cytometric analysis and PCR. Three experiments (3 male placentas) resulted in human hematopoietic repopulation of NOD-SCID mice ( Figure 3 and Table 3 ). hCD45 + cells ( Figure 3A) were detected in the blood of a NOD-SCID recipient receiving 20 3 10 6 placenta tissue cells from male term placenta (tP2). The BM and spleen contained high percentages of hCD45 + cells (51% and 22%, respectively) of which many were B lymphoid cells, with a few myeloid cells. Control transplantation of 20 3 10 6 human UCB cells showed similar levels of NOD-SCID BM engraftment (66% hCD45 + , 49% hCD19 + , and 6% hCD15 + cells) that were comparable to published cord blood NOD-SCID transplantation data (Bhatia et al., 1997) . Collagenase-treated placenta vessel cells (7 3 10 6 cells injected) from tP2 ( Figure 3B ) also resulted in similar engraftment, with high percentages of hCD45 + cells in BM and spleen, including B lymphoid and myeloid cells. Interestingly, injection of 7 3 10 6 vessel cells was sufficient to highly repopulate a NOD-SCID recipient, while injections of 5-6 3 10 6 tissue cells from tP3 and tP1 were not (Table 3 ). These data suggest that placental hu-SRCs are concentrated inside the placental labyrinth, possibly attached to the vascular endothelium. A combination of three enzymes (collagenase, dispase, and pancreatin) was used to further optimize placenta cell preparations. The improved digestion conditions resulted in a higher viable cell recovery (13-fold) and increased percentages of CD34 + CD38
+ and CD34 + CD38 À cells ( Figure S4 ), as compared to single collagenase treatment ( Figure 1B ). After injection of 10 3 10 6 cells from male tP3 (prepared using this method) into a NOD-SCID recipient, high percentages of hCD45 + cells were found in the blood, spleen, and BM ( Figure 3C ), and cells were of the B lymphoid and myeloid lineages. Moreover, the recipient mouse BM contained immature human CD34 + CD38 À cells, strongly suggesting that the term placenta contains bona fide hematopoietic progenitors/stem cells. The human hematopoietic cells detected in the flow cytometric analysis of NOD-SCID recipients ( Figures 3A, 3B , and 3C) transplanted with term placenta cells were derived from the fetal (male) part of the placenta, as shown by AMEL PCR analysis ( Figure 3D ) of BM, blood, spleen, lymph node, and thymus DNA. Thus, term human placenta contains fetal-derived hu-SRCs that home to the BM and provide robust long-term multilineage hematopoietic engraftment of recipients.
Human-Placenta-Derived Cell Lines Support Human Hematopoietic Progenitors and Possess Characteristics of Pericytes/Perivascular Placenta Cells
To examine whether the human placenta contains cells typical of a hematopoietic supportive microenvironment (i.e., mesenchymal stromal cells), cell lines were established at various developmental stages-3, 6, 16, 18, and 38 weeks of gestation. All the cell lines showed a fibroblastic morphology, and 2 cell lines from each developmental time point were analyzed.
The growth rates of the placenta cell lines varied. Early stage (maternally derived) and term placenta cell lines showed slower growth than cell lines from the first and second trimester tissues (Table 4 ). In agreement with the previously described cell surface phenotype of first trimester and term placenta stromal cells (Bhatia et al., 1997; Fukuchi et al., 2004; Li et al., 2005; Yen et al., 2005; Zhang et al., 2004 Zhang et al., , 2006 , our lines are CD13 + , CD29
lo/À , CD8 À , and CD11b lo/À ( Figure S5A ; Table   4 ). Also, in cultures allowing for osteogenic differentiation, our placenta lines (second trimester and term) were positive for alkaline phosphatase ( Figure S5B ) and mineralization, and most cell lines also could be differentiated into adipocytes ( Figure S5C ). Interestingly, when three of these cell lines were tested (H93-6, H92-1, and H91-2) in matrigel, they formed tubules indicative of endothelial potential ( Figure S5D ; Table 4 ). Thus, the human placental cell lines have the same mesenchymal potential as reported previously in hematopoietic supportive AGM (Durand et al., 2006) . Since a recent publication has highlighted pericytes/perivascular cells as the in vivo correlate/precursors to mesenchymal stromal/stem cells (Crisan et al., 2008) , we examined our cell lines for pericyte characteristics. Flow cytometric analyses showed that cell line H92-1 expressed pericyte markers NG2 and CD146 ( Figure 4A ), as did H93-6 and H91-1 (data not shown). To localize these cells in vivo, cryosections from week 16 human placenta were immunostained with three pericyte markers CD146, NG2, and a-SMA (smooth muscle actin) (Figures 4B and 4C) . As previously shown (Crisan et al., 2008) , the only cells coexpressing CD146, NG2, and a-SMA in situ are pericytes/perivascular cells closely associated to endothelial cells in microvessels (MV), capillaries (C), and large vessels (LV). These data demonstrate that placenta stromal cell lines at week 16 of gestation are pericyte-like cells, and together with data in Figures 1E and 1F , suggest that the perivascular/vascular microenvironment and the hematopoietic system develop in parallel in the placenta. The hematopoietic supportive properties of placenta stromal cell lines were tested in cocultures. Confluent monolayers of stromal cells (3, 16, and 18 week stages) were overlayed with 5000 CD34
+ UCB cells and cultured in factor-supplemented medium. After 12 days, the number of CD34 + cells was increased 2-to 8-fold (Table 4) . Clonogenic activity was also tested. As compared to the input number of CFU (in freshly sorted CB CD34 + cells), the placenta cell lines supported a 65-to 370-fold expansion of CFU-GM and an up to 8-fold expansion of CFU-Mix (Table 4 and Figure S6 ). Thus, based on the results of the cell lines, the human placenta contains hematopoietic supportive pericytes/perivascular stromal cells.
DISCUSSION
Prior to this study, only the presence of progenitors in the human placenta has been reported (Barcena et al., 2009 ). Here, we confirm that the human placenta contains all types of hematopoietic progenitors but more importantly, we show that the human placenta also contains hu-SRCs. hu-SRCs are detected Tissue DNA from all recipients injected with human placenta cells was tested for human engraftment by AMEL PCR. NOD-SCID adult recipients were irradiated with 3 Gy, injected intravenously with the indicated numbers of sorted placenta cells (and 1 3 10 5 NOD-SCID spleen cells), and analyzed for human cell engraftment 5 weeks postinjection. Rag gC À/À 5-day-old recipients were irradiated with 3 Gy, injected in the liver with the indicated numbers of sorted placenta cells (10 ml volume), and, 11 weeks postinjection, analyzed for human cell engraftment.
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Human Placenta Is a Potent Hematopoietic Niche in the human placenta as early as week 6 in gestation, throughout fetal development, and most surprisingly, at term. This is an unexpected result since previous data in the mouse term placenta show almost no adult repopulating HSCs (Gekas et al., 2005) . Given that human placenta cells throughout ontogeny provide long-term repopulation of the NOD-SCID hematopoietic system to the same levels and in the same hematopoietic lineages (B lymphoid and myeloid) as UCB cells, they are bona fide hu-SRCs (Cashman et al., 1997; Coulombel, 2004; Larochelle et al., 1996; Pflumio et al., 1996) . Thus, the human placenta can now be acknowledged as a new territory of hu-SRCs, and this routinely discarded tissue can now be used to provide further insight into cell-cell interactions and molecules relevant to human hematopoietic progenitor/stem cell growth. Our data demonstrate that the temporal sequence of hematopoietic cell appearance in the human placenta is generally conserved as compared to the mouse placenta. In the mouse, adult repopulating HSCs appear in the AGM region, vitelline, and Figure 3B . b Flow cytometric analysis of recipient shown in Figure 3A .
c Flow cytometric analysis of recipient shown in Figure 3C . d Flow cytometric analysis of recipient shown in Figure S7 .
Human Placenta Is a Potent Hematopoietic Niche umbilical arteries first and are thereafter found in the YS and placenta (de Bruijn et al., 2000; Dzierzak and Speck, 2008; Gekas et al., 2005; Ottersbach and Dzierzak, 2005) . In the human conceptus, hematopoietic progenitor/stem cells are found at day 27 in the aorta, concomitant to the appearance of clusters of cells closely adherent to the aortic lumenal wall (Tavian et al., 1996 (Tavian et al., , 1999 . Hematopoietic progenitors are found in the human YS, but with a less robust hematopoietic potential (Tavian et al., 2001 ). Our results indicate that fetal-derived hu-SRCs are present in the human placenta already at gestational week 6. The presence of HSCs at earlier stages, particularly between gestational weeks 3-6, is still undetermined. Most placentas we analyzed at these stages were of variable quality. Considering that, in the mouse placenta, limiting numbers of fetal-derived HSCs are found at E11 and rapidly increase to the highest numbers at E12 to E13 (Gekas et al., 2005; Ottersbach and Dzierzak, 2005) , our future analyses on the possible earlier appearance of HSCs in human placenta will depend on improved placenta isolation and more sensitive maternal/fetal genotyping. Another important and timely result comes from our panel of placental stromal cell lines. These cells are identified as CD146-and NG2-expressing pericyte-like cells. These stromal cell lines support the expansion of cord blood CD34 + cells and immature hematopoietic progenitors in cocultures. Interestingly, such pericyte-like cells were found in situ in the developing human placenta, suggesting an in vivo role in hematopoietic support. At all gestational stages, the placenta stromal cells express classical mesenchymal markers and, after gestation week 6, possess mesenchymal lineage potentials (osteo-and adipogenic), in agreement with other reported placenta cell lines (Fukuchi et al., 2004; Igura et al., 2004; Li et al., 2005; Miao et al., 2006; Parolini et al., 2008; Portmann-Lanz et al., 2006; Wulf et al., 2004; Yen et al., 2005; Zhang et al., 2006) . Since some mesenchymal cell lines constitute a suitable feeder layer for in vitro maintenance and/or expansion of primate and human ESCs (Kim et al., 2007; Miyamoto et al., 2004) and long-term cultureinitiating cells , it will be interesting to determine whether they are pericyte-like and are of maternal or fetal origin (In't Anker et al., 2004) . Our cell lines from gestation week 3 placenta were found to be maternally derived (by STR profiling) and exhibited slow growth, as compared to week 6, 16, and 18 placenta cell lines. Nonetheless, these cells effectively support the growth of CD34 + cells in cocultures, yielding an 8-fold increase in CFU-Mix. Maternal stromal cells, therefore, may contribute at early stages to hematopoietic support, and later in gestation, the more rapidly doubling fetal stromal cells predominate in the growth of the placenta as a highly vascular and hematopoietic territory. At early developmental time points (week 6 and 9), hematopoietic progenitors are in both the CD34 + and CD34 À fractions. CFU-GM and CFU-Mix are restricted initially to the Cell line origin was determined by STR profiling. The profile of R17-2 yielded only two alleles for each gene, while R17-3 gave a mix of alleles for many genes. ND, not done; M, maternal; F, fetal. 
CD34
À fraction of week 6 placenta and switch to the CD34 + fraction by week 15, suggesting developmental regulation of this marker on progenitors. Similarly, hu-SRCs are found in both CD34 + and CD34 À fractions at week 6. Later at week 16-20, hu-SRCs are in both fractions but appear to be more enriched in the CD34 + fraction. This is in agreement with the published data showing a subset of hu-SRCs in the CD34 À fraction of UCB (Bhatia et al., 1998; Wang et al., 2003 were found in the collagenase-treated vessel cell preparations (after extensive prewashing of the placenta to remove circulating blood) and in collagenase-treated placenta tissue. Since previous studies demonstrated the hematopoietic potential of human YS, embryonic liver, and fetal BM vascular endothelium (Oberlin et al., 2002) and also was suggested in the early mouse placenta (Corbel et al., 2007; Ottersbach and Dzierzak, 2005; Zeigler et al., 2006; Gekas et al., 2005) , our data support the notion that hu-SRCs are generated, harbored, and/or amplified in vascular labyrinth placenta niche. Finally, in addition to revealing the fundamental aspects of human placenta HSC development, our results have implications for the human placenta as source of HSCs alongside UCB for banking and potential clinical use. From our data, a conservative estimate of the HSC content of a human placenta (using the three enzyme treatment) is about 10% of the published number of HSCs contained in one unit of UCB (Bhatia et al., 1997; Wang et al., 1997) . As a 13-fold increase was already achieved through the implementation of three enzymes versus collagenase only, further increases in placenta hu-SRC harvest are expected. Importantly, if placental cells are to be a source of clinically useful HSCs, they must withstand storage procedures. In preliminary experiments, we found that the percentage of CD34 + placenta cells increased 1.4-fold and that hu-SRC potential was retained and enriched after storage in liquid nitrogen. Remarkably, only 1.3 3 10 6 thawed unsorted cells from placenta tP1 were required for robust NOD-SCID multilineage hematopoietic engraftment ( Figure S7 ) as compared to the low engraftment yielded with 6 3 10 6 freshly prepared collagenase-treated tP1 cells (Table 3) . Taken together, the human placenta is a highly hematopoietic tissue throughout development, containing potent hu-SRCs. As a rest tissue normally discarded in the birthing process, the human placenta can be considered as potential source for additional hematopoietic progenitor/stem cells useful for hematologic clinical applications and human regenerative medicine.
EXPERIMENTAL PROCEDURES Tissues and Cell Preparation
Human fetal tissues were obtained from elective abortions (CASA Clinics, Leiden and Rotterdam) and were contingent on informed consent. Umbilical cord blood and term placentas were obtained from vaginal deliveries or by Cesarean section. The use of fetal tissues was approved by the Medical Ethical Committee of the Erasmus Medical Center (MEC-2006-202) . Gestational age was determined by ultrasonic fetal measurements. Placenta cells were isolated directly or after overnight storage at 4 C. The umbilical cord was cut and removed, along with the amniotic sac and deciduas, from the placenta under sterile conditions. The outside of the placenta was washed with cold PBS/EDTA/PS (phosphate-buffered saline added with EDTA, penicillin [100 U/ml] and streptomycin [100 mg/ml]). The blood remaining inside the placenta was aspirated and collected (placenta blood), and the placental vasculature was flushed extensively with PBS/EDTA (up to ten times) via the umbilical vein and arteries to eliminate residual blood within the placental vascular labyrinth. Collagenase (0.125% w/v type I collagenase [Sigma] in PBS/10% fetal calf serum [FCS]/PS) was injected inside the placental vascular labyrinth. After 1 hr of incubation at 37 C, intravascular cells detached by the collagenase treatment were aspirated and collected (vessels collagenase). Placenta tissue was minced and washed thoroughly in cold PBS/FCS/PS and treated with 0.125% w/v type I collagenase in PBS/FCS/PS for 1 to 1.5 hr under agitation. Five grams of placenta tissue per 200 ml of buffer was found to be optimal for enzymatic digestion. The placenta was treated, in some cases, with Collagenase, Pancreatin (Sigma, 0.3%), and Dispase I (neutral protease grade I, Roche, 0.33 mg/ml) (three enzyme treatment). All enzymatic treatments were performed in presence of DNase (Sigma). Tissue was dissociated by repeated pipetting and passed through cotton gauze to eliminate nondigested tissue clumps, and the filtered cell suspension was washed twice. Mononuclear cells were recovered by Ficoll density gradient fractionation (Density 1.077 g/ml, Lymphoprep, Axis-Shield PoC AS), washed twice, and filtered through a 40 mm nylon cell strainer. Umbilical cord blood was diluted (1/2) into PBS/FCS/PS, and mononuclear cells were collected after Ficoll. Cells were washed, counted, and kept at 4 C for further utilization.
Enzyme Stock Solution Preparation
Pancreatin (2.5%) was prepared with pancreatin powder from porcine pancreas dissolved in 0.5% PVP solution (polyvinylpyrolidone K30, Fluka). DNase and dispase I (5 mg/ml) were prepared in sterile MilliQ water. Collagenase (2.5%) was prepared with collagenase powder dissolved in sterile PBS.
Mouse Transplantations and Posttransplantation Tissue Collection
Cells from placenta preparations or placenta cells sorted on the basis of CD34 expression (along with 1-2 3 10 5 helper spleen cells) were intravenously injected into irradiated (3 to 3.5 Gy) NOD-SCID (adult) or intrahepatically into Rag gC À/À (5-day-old) mice. Four weeks to 5 months later, hematopoietic tissues were collected. Peripheral blood was diluted and mononuclear cells were isolated using Ficoll or lysing solution. Spleen, lymph nodes, and thymus were crushed separately on a 40 mm nylon cell strainer. BM cells were flushed from the femurs and tibias of recipient mice. For all tissues collected, cells were kept for further DNA analyses.
Flow Cytometry Analysis
Placenta cells were stained with the following antibodies: purified CD16/CD32 (preblock), fluorescein isothiocyanate (FITC) or APC-human (h)CD34, FITCmouse (m)CD45, phycoerythrin (PE) or PE Cy7-hCD38, FITC-hCD31, and PE or PerCP Cy5.5-hCD45. Cells from tissues of NOD-SCID or Rag gC À/À recipient mice were stained with the following antibodies: purified CD16/CD32, FITC or PE or PerCP-Cy5.5-hCD45, FITC or PE-mCD45, FITC-hCD15, PE-hCD19, FITC-hCD34, PE-hCD38, PE Cy7-hCD14, and APC Cy7-HLA-DR. After 30 min of staining, cells were washed and stained with 7AAD (Molecular Probes, Leiden, NL) or Hoechst 33258 (1 mg/ml, Molecular Probes) for dead cell exclusion. Blood samples from a noninjected mouse and from informed consent individuals were used as controls. Stromal cell lines were stained with primary antibodies NG2 and CD146, followed by goat anti-mouse Alexa 488. All antibodies were from BD PharMingen, Immunotech or Invitrogen, and analyses were performed on a FACScan or Aria (Becton Dickinson).
Immunohistochemistry Cryosections (7 mm) of human placenta (1 to 2 cm pieces) were prepared and immunostained as described previously (Crisan et al., 2008 with an inverted microscope after day 21 and 28 of culture.
Generation of Human Placenta-Stromal Cell Lines
Placenta tissues were dissected into small pieces and explant cultured on 0.1% gelatin coated 6-well plates at the air-medium interface in hu-LTCSM medium (50% H5100, Stem Cell Technologies; 15% heat-inactivated FCS, GIBCO; 35% a-MEM, GIBCO; 1% Pen/Strep, GIBCO; 1% Glutamax-I (1003), GIBCO; 10 mM b-mercaptoethanol, Merck) at 37 C, 5% CO 2 . After several days, cells were harvested using trypsin-EDTA and were seeded on new precoated dishes supplemented with 20% filtered supernatant from the previous passage. Six lines per placenta at 3, 6, 16, and 18 weeks of gestation and 11 lines from term placentas were established. Lines were checked daily and split when subconfluency was reached. Growth curves were established from passage 3 onward.
Mesenchymal Differentiation
Osteogenic differentiation was performed in Dulbecco's modified Eagle's medium (DMEM) (GIBCO) containing 15% heat-inactivated FCS (GIBCO), 1% PS (GIBCO), 200 mM ascorbic acid (Sigma), 10 mM b-glycerophosphate (Sigma), and 10 À7 M dexamethasone (Sigma). Cells were seeded in uncoated 6-well plates (500, 1000, and 2000 cells/cm 2 ) and incubated at 37 C. After 11 and 14 days, alkaline phosphatase activity was determined (Sigma) and at 28 days, Alazarin Red staining was performed (Sigma). Adipocyte differentiation of subconfluent cells was performed in DMEM (10% FCS), dexamethasone (1 mM), IBMX (500 mM), indomethacin (60 mM), and 5 mg/ml insulin for 7 days. Cells were stained with oil red. Endothelial differentiation was performed as previously described (Chen et al., 2009 ) on Matrigel Matrix (BD Matrigel Basement Membrane Matrix, 354234) precoated 96-well dishes (50 ml/well) and incubated at 37 C for 40 min. Stromal cells (1 3 10 4 ) were seeded on top of matrigel, incubated at 37 C, and observed up to 6 hr.
Hematopoietic Supportive Stromal Cocultures
Mononuclear cord blood cells were sorted on a FACSAria (Becton Dickinson) based on CD34 expression and Hoechst 33258 exclusion (Molecular Probes). 5000 CD34 + CB cells were cocultured with a preestablished confluent irradiated layer (12 Gy) of human stromal cell lines in a 24-well plate using h-LTCSM medium, supplemented with hFLT3 (50 ng/ml), hSCF (100 ng/ml), and hTPO (20 ng/ml). After 12 days of coculture, cells were harvested, counted, analyzed by flow cytometry, and plated in hematopoietic colony assays.
Conventional PCR Analysis
Embryo gender was determined by PCR amplification of the amelogenin locus (AMEL) (Sullivan et al., 1993 ) that differs in size on the X (106 bp) and Y (112 bp) chromosomes. PCR mixture contained AmpliTaq DNA polymerase PCR Buffer (15 mM MgCl 2 ; Roche, Applied Biosystems), 200 mM of each dNTP, 400 nM of each primer, 0.01 U/ml of SuperTaq DNA polymerase (HT Biotechnology, Applied Biosystems), and products were separated on a 4% agarose gel. Human chromosome 17 a-satellite PCR (Chr 17) (Becker et al., 2002) mixture contained AmpliTaq DNA polymerase PCR Buffer (15 mM MgCl 2 ), 200 mM of each dNTP, 250 nM of each primer, MgCl 2 2 mM, and 0.01 U/ml of SuperTaq DNA polymerase, and yields a PCR product of 850 bp. Conditions for all PCRs are in Table S1 . 0.5-3 micrograms of DNA from hematopoietic tissues of recipient mice or in vitro cultures was used for AMEL PCR, and 0.25-0.5 mg DNA was used for human Chr 17 PCR. Limits of sensitivity of human AMEL PCR and Chr 17 PCR were both 1 human cell in 10 5 mouse cells.
STR Typing
Human embryo samples and recipient mouse tissue samples were profiled using the PowerPlex 16 System Kit (Promega) as usually applied to human identity testing in forensic DNA analysis. PCR mixtures contained 1.3 ml Gold Star 103 Buffer, 1.3 ml PowerPlex16 103 Primer Pair Mix, 2U of AmpliTaq Gold DNA polymerase (Roche, Applied Biosystems), and 1 ng of human genomic DNA or 50-200 ng of DNA from mouse samples. PCR was done as described in Table S1 using the PTC-200 Thermal Cycler from MJ Research (Bio-Rad). One microliter of PCR product was mixed with 9.6 ml of Hi-Di Formamide (Applied Biosystems) and 0.4 ml of internal lane standard ILS 600 and denatured at 95 C for 3 min. Amplified fragments were detected using the ABI PRISM 3100 Genetic Analyzer (Applied Biosystems), and data were analyzed with the GeneMapperID v3.2 software (Applied Biosystems). The statistical certainty of the profiles obtained from each reconstituted mouse was established by calculating the random match probability with correction for potential allele sharing with the mother (Weir, 2003) . For the 19 week placenta recipient ( Figure 2E ; Table 1 ) displaying a complete profile, the probability of a match with a profile among a selection of unrelated and related individuals (i.e., not from the embryonic source) was estimated at 8.65 3 10 À12 .
For the three 8 week placenta recipients showing a partial profile (Table 1) , this probability was estimated at 6.87 3 10 À11 , 1.89 3 10 À8 , and 3.73 3 10 À7 respectively. Estimations are based on the European population and may slightly vary if non-European populations are taken in account. The limit of sensitivity of STR profiling in which a complete profile could be obtained was 1 human cell in 1-2 3 10 3 mouse cells.
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